Answers are grounded in this paper and cite their sources.
Hyperglycemia is the hallmark characteristic of diabetes mellitus.Blood glucose and hemoglobin A1c are guideline-driven markers useful for diagnosis and monitoring treatment.But blood glucose is but 1 part of this systemic metabolic disease that also has infl ammatory components."Successful" aggressive control of blood sugar has had limited success in preventing the onset and progression of cardiovascular and renal damage.Many of our patients still struggle with ischemic heart disease, heart failure, peripheral arterial disease, and kidney disease.There have been several new US Food and Drug Administration (FDA)-approved medications to treat type 2 diabetes, some of which use unique physiologically targeted mechanisms to lower blood glucose.The FDA drug approval process has mandated that increased attention be given to studying the effects of potential diabetes drugs on the systemic components of diabetes mellitus, not just on their hypoglycemic activity.The initial focus was on excluding unanticipated detrimental cardiovascular effects.Studies were large, with prospectively planned collection of detailed cardiovascular and renal data, and cardiovascular events were carefully adjudicated.As a result, it was demonstrated that some of the newer drugs capable of lowering the glucose by novel mechanisms were not only cardiac safe, but somewhat surprisingly were able to reduce several cardiac (and renal) morbidities.Jaswaney et al 1 in this issue of the Journal discuss the use of the sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with heart failure and chronic kidney disease, including those without type 2 diabetes.These drugs are effective adjuncts in lowering glucose and A1c levels.Designed to work by inducing glucosuria with anticipated reductions in circulating insulin levels in patients with type 2 diabetes, there was reason to think that they could reduce some of the metabolic components of type 2 diabetes that might be exacerbated by hyperinsulinemia.It was a welcome surprise (and a bit confusing) to many of us not practicing primarily in the diabetes arena that the clinical trials for multiple drugs in this class demonstrated effi cacy in decreasing heart failure admissions (for patients with reduced as well as maintained ejection fraction), all-cause and cardiovascular mortality, and progression of chronic kidney disease.And, these benefi ts were also found in patients without type 2 diabetes.Perhaps also surprisingly, the incidences of myocardial infarction and stroke apparently were not signifi cantly reduced, 2 raising further questions about mechanism of action.But it seems quite unlikely that these benefi ts are from the induced glucosuria and the resultant relative hypoglycemia.So how does gout enter into this discussion?Gout is a prototypic autoinfl ammatory disease that may occur in patients with long-standing hyperuricemia (generally defi ned as a level above urate's estimated in vivo saturation point of 6.8 mg/dL), which can result in the deposition of monosodium urate in and around joints and sometimes in organs, including the kidney.The physiologic basis for hyperuricemia in most patients is ineffi cient intestinal and renal excretion, the latter being due to excess reabsorption of uric acid in the proximal tubules.Although it is the dramatic
No takes yet. Share an insight, caveat, or question.
Brian F. Mandell (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: